Primary Site >> Pancreatic Cancer
Gene >> GCG
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Molecular forms of glucagon-like peptide-1 in human pancreas and glucagonomas. PMID: 2991321 |
Ref: Inhibition of pancreatic glucagon gene expression in mice bearing a subcutaneous glucagon-producing GLUTag transplantable tumor. PMID: 1491697 |
Ref: Glucagon-like peptide-1 (GLP-1) molecular forms in human pancreatic endocrine tumors resemble those in intestine rather than pancreas. PMID: 7835211 |
Ref: Concomitant point mutation of tumor suppressor gene p53 and oncogene c-N-ras in malignant neuroendocrine pancreatic tumor. PMID: 9042254 |
Ref: Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. PMID: 10580424 |
Ref: [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. PMID: 17138746 |
Ref: Genotype and haplotype analysis of TP53 gene and the risk of pancreatic cancer: an association study in the Czech Republic. PMID: 20110284 Ref: Differentiation of pancreatic acinar cells to hepatocytes requires an intermediate cell type. PMID: 20178796 |
Ref: Identification of serum proteins involved in pancreatic cancer cachexia. PMID: 21094171 Ref: Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. PMID: 21334333 Ref: The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. PMID: 21484979 Ref: Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. PMID: 21680696 Ref: A novel pancreatropic coxsackievirus vector expressing glucagon-like peptide 1 reduces hyperglycemia in streptozotocin-treated mice. PMID: 21937637 |
Ref: Dickkopf-3 maintains the PANC-1 human pancreatic tumor cells in a dedifferentiated state. PMID: 21879258 Ref: 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma. PMID: 22170321 Ref: GLP1 and cancer: friend or foe? PMID: 22691625 |
Ref: Incretin-based therapies in the treatment of type 2 diabetes--more than meets the eye? PMID: 23375875 Ref: Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. PMID: 23440284 Ref: A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. PMID: 23645884 Ref: A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe? PMID: 23645885 Ref: The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits. PMID: 24073725 |
Ref: Occurrence of spontaneous pancreatic lesions in normal and diabetic rats: a potential confounding factor in the nonclinical assessment of GLP-1-based therapies. PMID: 24222349 Ref: Expression of glucagon-like Peptide 1 receptor and its effects on biologic behavior in pancreatic neuroendocrine tumors. PMID: 24326362 Ref: Sitagliptin: a review of its use in patients with type 2 diabetes mellitus. PMID: 24407560 Ref: Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway. PMID: 24641303 Ref: Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner. PMID: 24801389 Ref: Pre-clinical evaluation of [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 for imaging of insulinoma. PMID: 24857864 Ref: Incretin-mimetic therapies and pancreatic disease: a review of observational data. PMID: 25180611 Ref: Balancing benefits and risks in patients receiving incretin-based therapies: focus on cardiovascular and pancreatic side effects. PMID: 25391858 Ref: Adverse Effects of GLP-1 Receptor Agonists. PMID: 26177483 |
Ref: Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer. PMID: 25363438 Ref: Pancreatic Neuroendocrine Tumors in Mice Deficient in Proglucagon-Derived Peptides. PMID: 26192435 Ref: Significance of expression of glucagon-like peptide 1 receptor in pancreatic cancer. PMID: 26238361 |
Ref: The importance of Pharmacovigilance for the drug safety: Focus on cardiovascular profile of incretin-based therapy. PMID: 26461922 Ref: GLP-1 mimetic drugs and the risk of exocrine pancreatic disease: Cell and animal studies. PMID: 26751948 |
Ref: Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss. PMID: 28027898 Ref: Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes. PMID: 28249585 Ref: Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, mul PMID: 28344112 |
Ref: Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. PMID: 29221659 Ref: Pancreatic cancer-derived exosomes suppress the production of GIP and GLP-1 from STC-1cells in vitro by down-regulating the PCSK1/3. PMID: 29800682 Ref: Recent Topics Around Multiple Endocrine Neoplasia Type 1. PMID: 29897580 Ref: The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications. PMID: 30135132 Ref: Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. PMID: 30246878 Ref: Cucurbitacin B Induces Hypoglycemic Effect in Diabetic Mice by Regulation of AMP-Activated Protein Kinase Alpha and Glucagon-Like Peptide-1 via Bitter Taste Receptor Signaling. PMID: 30298009 |